Literature DB >> 28616797

The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP.

Suzan Guven Yilmaz1,2, Cumali Degirmenci3, Yunus Emre Karakoyun3, Emil Yusifov3, Halil Ates3.   

Abstract

PURPOSE: To evaluate the effect of bimatoprost/timolol maleate fixed combination (BTFC), latanoprost/timolol maleate fixed combination (LTFC), and travoprost/timolol maleate fixed combination (TTFC) on 24-h intraocular pressure (IOP) in patients with open-angle glaucoma.
METHODS: This prospective, observer-masked, randomized study included 50 patients with primary open-angle glaucoma. All patients were using hypotensive lipids and timolol maleate fixed combination treatment for ≥4 weeks and had an IOP ≤ 21 mmHg. Group 1 (n = 18) received BTFC, group 2 (n = 14) received LTFC, and group 3 (n = 18) received TTFC. All patients were hospitalized, and IOP was monitored for 24-h (10:00, 14:00, 18:00, 22:00, 02:00, and 06:00). Mean diurnal IOP variation measurements were taken between 06:00 and 18:00, and mean nocturnal IOP variation measurements were taken between 22:00 and 02:00. Mean IOP and IOP variation in the three groups were compared.
RESULTS: Mean 24-h IOP did not differ significantly between the three groups (group 1: 14.6 ± 2.9 mmHg; group 2: 14.1 ± 3.7 mmHg and group 3: 15.8 ± 2.0 mmHg; P > 0.05). Mean diurnal IOP variation was 4.6 ± 2.3 mmHg in group 1, 5.8 ± 2.4 mmHg in group 2, and 4.3 ± 1.7 mmHg in group 3, and mean nocturnal IOP variation was 3.2 ± 2.8 mmHg in group 1, 2.9 ± 1.9 mmHg in group 2, and 3.0 ± 1.6 mmHg group 3. There were not any significant differences in diurnal or nocturnal IOP variation between the three groups (P < 0.05).
CONCLUSION: All three fixed combinations effectively controlled IOP for 24-h and had a similar effect on diurnal and nocturnal IOP variations.

Entities:  

Keywords:  24-h IOP; And travoprost/timolol maleate; Bimatoprost/timolol maleate; Latanoprost/timolol maleate

Mesh:

Substances:

Year:  2017        PMID: 28616797     DOI: 10.1007/s10792-017-0601-8

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  23 in total

1.  Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol.

Authors:  Stephan Dunker; Achmed Schmucker; Hubert Maier
Journal:  Adv Ther       Date:  2007 Mar-Apr       Impact factor: 3.845

2.  Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies.

Authors:  Anastasios G P Konstas; Liliane Bányai; Klaus-Dieter Blask; Jutta Väth; Vassilios P Kozobolis; Peter R Trüb; Sevasti Tsironi; Stefanos Maloutas; Miguel A Teus; William C Stewart
Journal:  J Ocul Pharmacol Ther       Date:  2004-10       Impact factor: 2.671

3.  [Comparison of intraocular pressure lowering efficacy of bimatoprost / timolol fixed combination and other glaucoma medications in the treatment of glaucoma].

Authors:  K Skorkovská
Journal:  Cesk Slov Oftalmol       Date:  2008-07

Review 4.  Interventions for improving adherence to ocular hypotensive therapy.

Authors:  Trish A Gray; Lois C Orton; David Henson; Robert Harper; Heather Waterman
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

5.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

Authors:  Anders Heijl; M Cristina Leske; Bo Bengtsson; Leslie Hyman; Boel Bengtsson; Mohamed Hussein
Journal:  Arch Ophthalmol       Date:  2002-10

Review 6.  Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial.

Authors:  M Cristina Leske; Anders Heijl; Leslie Hyman; Bo Bengtsson; Eugene Komaroff
Journal:  Curr Opin Ophthalmol       Date:  2004-04       Impact factor: 3.761

7.  Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study.

Authors:  Joseph Caprioli; Anne L Coleman
Journal:  Ophthalmology       Date:  2008-02-20       Impact factor: 12.079

8.  The Effect of Diurnal Fluctuation in Intraocular Pressure on the Evaluation of Risk Factors of Progression in Normal Tension Glaucoma.

Authors:  Seung Hoon Kim; Eun Jung Lee; Jong Chul Han; Sae Woon Sohn; Taekkwan Rhee; Changwon Kee
Journal:  PLoS One       Date:  2016-10-24       Impact factor: 3.240

9.  Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study.

Authors:  J A Kammer; B Katzman; S L Ackerman; D A Hollander
Journal:  Br J Ophthalmol       Date:  2009-09-01       Impact factor: 4.638

10.  Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost.

Authors:  Yuko Maruyama; Yoko Ikeda; Kazuhiko Mori; Morio Ueno; Haruna Yoshikawa; Shigeru Kinoshita
Journal:  Clin Ophthalmol       Date:  2015-08-07
View more
  4 in total

Review 1.  Topical Medication Therapy for Glaucoma and Ocular Hypertension.

Authors:  Tao Wang; Linlin Cao; Qikun Jiang; Tianhong Zhang
Journal:  Front Pharmacol       Date:  2021-12-01       Impact factor: 5.810

2.  Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study.

Authors:  Sonja Jandroković; Sania Vidas Pauk; Dina Lešin Gaćina; Ivan Skegro; Martina Tomić; Sanja Masnec; Tomislav Kuzman; Miro Kalauz
Journal:  Clin Ophthalmol       Date:  2022-09-28

Review 3.  Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma.

Authors:  Uday B Kompella; Rachel R Hartman; Madhoosudan A Patil
Journal:  Prog Retin Eye Res       Date:  2020-09-04       Impact factor: 21.198

Review 4.  Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients.

Authors:  Ziyan Cai; Mengdan Cao; Ke Liu; Xuanchu Duan
Journal:  J Ophthalmol       Date:  2021-05-25       Impact factor: 1.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.